Optical Molecular Imaging of Multiple Biomarkers of Epithelial Neoplasia: Epidermal Growth Factor Receptor Expression and Metabolic Activity in Oral Mucosa  by Rosbach, Kelsey J. et al.
Optical Molecular Imaging




Activity in Oral Mucosa1
Kelsey J. Rosbach*, Michelle D. Williams†,
AnnM.Gillenwater‡ andRebecca R. Richards-Kortum*
*Department of Bioengineering, Rice University, Houston,
TX; †Department of Pathology, MD Anderson Cancer
Center, Houston, TX; ‡Department of Head and Neck
Surgery, MD Anderson Cancer Center, Houston, TX
Abstract
Biomarkers of cancer can indicate the presence of disease and serve as therapeutic targets. Our goal is to develop
an optical imaging approach using molecularly targeted contrast agents to assess several centimeters of mucosal
surface for mapping expression of multiple biomarkers simultaneously with high spatial resolution. The ability to
image biomarker expression level and heterogeneity in vivo would be extremely useful for clinical cancer research,
patient selection of personalized medicine, and monitoring therapy. In this proof-of-concept ex vivo study, we ex-
amined correlation of neoplasia with two clinically relevant biomarkers: epidermal growth factor receptor (EGFR)
and metabolic activity. Two hundred eighty-six unique locations in nine samples of freshly resected oral mucosa
were imaged after topically applying optical imaging agents EGF–Alexa 647 (to target EGFR) and 2-(N -(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (to target metabolic activity). Quantitative features were calculated from
resulting fluorescence images and compared with tissue histopathology maps. The EGF–Alexa 647 signal corre-
lated well with EGFR expression as indicated by immunohistochemistry. A classification algorithm for presence
of neoplasia based on the signal from both contrast agents resulted in an area under the curve of 0.83. Regions
with a posterior probability from 0.80 to 1.00 contained more than 50% neoplasia 99% (84/85) of the time. This
study demonstrates a proof-of-concept of how noninvasive optical imaging can be used as a tool to study expres-
sion levels of multiple biomarkers and their heterogeneity across a large mucosal surface and how biomarker char-
acteristics correlate with presence of neoplasia. Applications of this approach include predicting regions with the
highest likelihood of disease, elucidating the role of biomarker heterogeneity in cancer biology, and identifying
patients who will respond to targeted therapy.
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Introduction
The molecular changes that accompany the dysplasia-to-carcinoma
sequence can serve as diagnostic aids, therapeutic targets, indicators
of recurrence, or as surrogate end points in clinical trials of targeted
therapeutics [1–4]. For example, in patients with breast cancer, estro-
gen receptor positivity as indicated by immunohistochemistry (IHC)
not only is associated with improved prognosis but also qualifies the
patient for targeted hormonal therapy such as tamoxifen [5]. When it
was recently discovered that 90% of gastrointestinal stromal tumors
have an activating mutation in the KIT (CD117) receptor tyrosine
kinase gene, investigators evaluated a KIT inhibitor, imatinib, for
treatment and found dramatically improved patient survival [6].
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Whereas many promising biomarkers of neoplasia have been iden-
tified, only a few are routinely used in clinical decision making. In
part, this is due to the lack of tools available to quantitatively assess
biomarker expression in vivo at the point-of-care, which limits dis-
covery of the role that biomarkers play in cancer progression. Al-
though hematologic cancers tend to be clonal, solid tumors are
frequently extremely heterogeneous. Standard biomarker assessment
is currently performed on small biopsy specimens that may not re-
flect the heterogeneity of a large solid tumor. To achieve the poten-
tial of molecular management of neoplasia, there is an important
need to better understand how the spatial and temporal changes in
biomarker expression correlate with disease progression and to develop
methods to noninvasively assess in vivo expression of these biomarkers
before, during, and after therapy.
To assess the feasibility of using optical imaging to simultaneously
map expression of multiple biomarkers in mucosal surfaces, we per-
formed a proof-of-concept study in freshly resected human surgical
specimens from patients with oral cancer. We demonstrate that such
maps correlate both with biomarker expression and with histologic
diagnosis, and we show that they can be used to predict tissue regions
with the highest likelihood of disease.
In the optical molecular imaging approach used in this study, a
solution containing a targeted, fluorescent contrast agent is applied
topically to a tissue at risk. The use of topical application is an alter-
nate mode of delivering contrast agents compared with intravenous
injection that is applicable to both ex vivo and in vivo imaging. It has
many benefits, including a decreased required dose and only local
exposure, thereby potentially reducing systemic toxicity concerns. Top-
ical application is also associated with shorter incubation times. In the
oral cavity, a mouthwash or topical gel formulation could be used to
topically apply targeted imaging agents in patients. The tissue is then
rinsed and imaged to yield a spatial map of biomarker expression that
can be used to guide clinical decision making, aiding in the early detec-
tion of neoplasia, staging of disease, selecting and monitoring therapy,
detecting recurrence, and predicting the likelihood of progression. Al-
though the study reported here was conducted using freshly resected
oral tissue, the concept could be translated to live patient oral cavity
imaging once regulatory requirements are fulfilled. Such an approach
using topical application of a fluorescent imaging agent in vivo to detect
colonic neoplasms was recently demonstrated [7].
Optical molecular imaging has potential advantages over the two
most widely used techniques to assess biomarker expression levels:
IHC and reverse transcription–polymerase chain reaction. Most
frequently, IHC is used to assess protein expression in vitro in his-
tologic specimens. The limitations of IHC include the need to re-
move tissue for assessment, difficulty in quantifying biomarker
expression levels, and challenges associated with examining multiple
biomarkers per slide, unless the proteins of interest lie in distinct
compartments within the cell [8]. Information from multiple bio-
markers frequently outperforms information from a single marker
alone [5]. Breast cancer presents a good example of this in clin-
ical practice, where estrogen receptor, progesterone receptor, and
HER2/neu expression are all routinely assessed for prognosis and
selection of therapy. Conversely, reverse transcription–polymerase
chain reaction and other high-throughput methods to altered
mRNA expression associated with neoplasia can be used to simul-
taneously assess thousands of potential biomarkers. However, gene
expression profiling requires tissue removal, and it is difficult to
assess information about spatial distribution of biomarker changes.
It is also not clear that changes in gene expression lead to changes in
protein expression.
Optical molecular imaging using targeted contrast agents, however,
is ideally suited to achieve the goal of spatial and temporal assessment
of biomarker expression in vivo. Optical molecular imaging can be
used to noninvasively image the distribution of multiple biomarkers
across a large mucosal surface in vivo. Optical molecular imaging has
been used to image eight or more biomarkers in distinct spectral bands
with high spatial resolution and may serve as an important tool in better
understanding the role of biomarkers in the disease process [9].
The goal of this study was to explore the role of optical imaging
with multiple topically applied targeted contrast agents to study the
heterogeneity of biomarker expression and its correlation with the pres-
ence of neoplasia across a large mucosal surface area. The oral cavity was
chosen as an organ site because of its accessibility to optical imaging. Op-
tically active contrast agents targeting two clinically relevant biomarkers,
the epidermal growth factor receptor (EGFR) and metabolic activity,
were applied to the tissue surface, and the resulting optical molecular
images were compared with the gold standard of histopathology.
EGFR is one of the most commonly studied biomarkers in cancers
of the oral cavity because it is widely overexpressed in oral squamous
cell carcinoma and dysplasia [10]. Although the reported percentage
of patients with overexpression of EGFR varies between studies, a
review from Lippman et al. [11] indicates that 80% to 100% of pa-
tients with premalignant or malignant oral lesions have high EGFR
expression [11]. A recent study from Taoudi Benchekroun et al. [12]
found that 71% of oral premalignant lesions display high EGFR ex-
pression levels, which correlated with a greater risk of developing oral
cancer. EGFR expression level also increases with the progression of
disease [13–16]. The prevalence of EGFR expression makes it a poten-
tially useful target to improve detection and guide treatment; in fact,
the EGFR inhibitor, cetuximab, is approved by the US Food and Drug
Administration (FDA) for head and neck cancer therapy.
Another clinical biomarker for oral cancer is increased metabolic
activity. Metabolism is elevated in dysplasia and cancer due to rapid
cell growth and division; consequently, glucose transporters (GLUTs)
are often overexpressed or operate at a higher activity level. In a study
by Kunkel et al., 100% (40/40) of oral cancers expressed GLUT-1 by
IHC, and Mellanen et al. found that every tumor sample they exam-
ined expressed either GLUT-1 or GLUT-3 mRNA [17,18]. Ayala
et al. [19] found GLUT-1 overexpression in 50% of their oral cancer
specimens, Tian et al. [20] observed that 73.7% of samples had mod-
erate to strong GLUT-1 expression, and Ohba et al. [21] discovered
that overexpression of GLUT-1 in the invasion front is associated
with the tumor depth and prognosis.
Materials and Methods
Preparation of Fluorescent Imaging Agents
To assess EGFR expression, the natural ligand of EGFR, the EGF,
was conjugated to a fluorescent dye. Purified human-derived recom-
binant EGF peptide (Calbiochem, San Diego, CA) was conjugated
to Alexa Fluor 647–carboxylic ester (Invitrogen, Carlsbad, CA). Ex-
cess free dye was removed by size exclusion chromatography followed
by dialysis. The resulting EGF–Alexa 647 imaging agent was diluted
to a final concentration of 25 μg/ml in sterile 1× phosphate-buffered
saline (PBS) with 10% dimethylsulfoxide as a permeation enhancer.
Specificity studies in both cells and resected human tissue have been pre-
viously performed and published with EGF–Alexa 647, demonstrating
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the ability of this agent to specifically target EGFR in cell culture and
in oral mucosa [22].
A fluorescently labeled glucose molecule was used to assess meta-
bolic activity. 2-(N -(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose (2-NBDG) is a commercially available optical glucose
analog (Invitrogen, Carlsbad, CA). 2-NBDG was diluted to a con-
centration of 0.16 mM in sterile 1× PBS. Multiple studies have used
2-NBDG as a metabolic activity indictor [23–25]. Tumor cells in
culture have been shown to take up approximately five times the
amount of 2-NBDG compared with nonmalignant cells, and com-
petition assays with free glucose decreased the amount of 2-NBDG
that was taken up [23]. A recent study by Sheth et al. [24] demon-
strated the comparability of 2-NBDG to FDG-PET imaging in several
preclinical examples, and Nitin et al. [25] demonstrated the potential
use of 2-NBDG for detecting neoplasia in clinical specimens, in which
dysplasia and cancer displayed a two- to five-fold increase in fluores-
cence intensity compared with normal tissue.
Application of Fluorescent Imaging Agents to Clinical Samples
To evaluate the ability of 2-NBDG and EGF–Alexa 647 to iden-
tify neoplasia in human oral tissue, freshly resected clinical specimens
were obtained from patients undergoing surgery at MD Anderson
Cancer Center. These patients gave written informed consent to
participate in the study, which was approved by the Institutional
Review Boards at both MD Anderson Cancer Center and Rice Uni-
versity. Neoplastic tissue was obtained immediately after surgical resec-
tion and taken to a laboratory for contrast agent application and
subsequent imaging.
To assess autofluorescence before the application of any fluorescent
contrast agents, the tissue was imaged with a multispectral digital
microscope (MDM), a wide-field imaging system that has been described
in detail previously [26]. Briefly, the MDM is a dental microscope that
has been modified with fluorescence excitation and emission filters
and a mercury-argon light source; it is capable of imaging in both
reflectance and fluorescence modes. It has a large field of view (∼5 ×
7 cm) and can achieve a lateral spatial resolution up to 0.016 mm. Pre-
incubation images of the tissue were taken using standard white light
setting and the filter configurations for 2-NBDG (excitation = 475 nm,
emission = 550 nm) and EGF–Alexa 647 (excitation = 650, emission =
670 nm) to allow later subtraction of tissue autofluorescence from post-
incubation images.
After autofluorescence imaging, 2-NBDG solution was topically
applied to the epithelial surface of the resected oral tissue and placed
in an incubator at 37°C for 20 minutes. After incubation with 2-
NBDG, the tissue was briefly rinsed with sterile 1× PBS to remove
any excess unbound fluorescent contrast agent. The tissue was again
imaged with the MDM using the filter configurations for 2-NBDG
and EGF–Alexa 647. Next, EGF–Alexa 647 in 10% dimethylsulfoxide
was topically applied to the epithelial surface of the tissue and incubated
for 20 minutes at 37°C. The tissue was briefly rinsed with sterile 1×
PBS and imaged using appropriate filter settings on the MDM.
Once imaging was complete, the entire tissue was returned to the
Pathology Department of MD Anderson Cancer Center. The tissue
was processed following standard procedures: the tissue was thinly
sliced anterior to posterior and placed into cassettes for hematoxylin
and eosin (H&E) staining. Locations of pathology cuts were doc-
umented, and the portion of the tissue that was placed into each
cassette was recorded to allow for future correlation to pathology.
Neither 2-NBDG nor EGF–Alexa 647 affects histopathology pro-
cessing or staining.
Creation of Histopathology Maps
To compare the results of wide-field imaging with the gold stan-
dard of histopathology, a two-dimensional color-coded pathology
map was created for each clinical specimen. To create this map, all the
H&E slides for each specimen were reviewed by an expert head and
Figure 1. Images from two representative specimens. From left to right, images include a white light photograph, fluorescence after
incubation with EGF–Alexa 647 to show EGFR expression, fluorescence after incubation with 2-NBDG to show metabolic activity, and the
corresponding histopathology map. The specimen shown in the top row had a worst diagnosis of moderate dysplasia; the specimen in the
bottom row had a worst diagnosis of cancer. Scale bars, 1 cm. The color scale on the bottom shows the key for the histopathology maps.
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neck pathologist blinded to the optical images (M.W.). The diagnosis
across the entire epithelium was recorded for each slide. This expert
diagnosis from the slide was assumed to represent the diagnosis for
the entire thickness of the thin piece of tissue that was placed in the
corresponding cassette. The diagnose of normal epithelium; mild, mod-
erate, and severe dysplasia; and cancer were all assigned a unique color
code. On the basis of detailed notes of where the tissue was sliced and of
the diagnosis across the epithelium for each piece of tissue, the color-
coded histopathology map was created as an overlay on top of the white
light image of the clinical specimen. The resulting two-dimensional
histopathology map was used as a gold standard to compare with the
wide-field fluorescence images. Creation of a histopathology map is not
standard practice in pathology, and to create an accurate map, the tissue
had to have a fairly flat surface, slicing had to be strictly monitored and
documented, and a detailed pathology reading across the entire surface
had to be obtained and recorded. All the tissue samples used in this
study met these criteria.
Immunohistochemistry
The Histology Core Laboratory at MD Anderson Cancer Center
performed immunohistochemical staining for EGFR on multiple
specimens to confirm that optical molecular imaging results corre-
lated with the gold standard of IHC for the presence of EGFR.
Immunohistochemical analysis was performed using the automated
BOND MAX immunohistochemical stainer by Vision Biosystems
(Norwell, MA) using the standard clinically used antibody and pro-
tocol for EGFR (clone 31G7 mouse antihuman; 1:50; Zymed, South
San Francisco, CA). An expert head and neck pathologist reviewed these
slides to grade the intensity of staining across the entire epithelial surface.
The scale used for assessment of intensity of EGFR immunostaining
Figure 2. A representative set of images to demonstrate the correlation between EGF–Alexa 647 fluorescence intensity and IHC for
EGFR. (A) Wide-field fluorescence image of specimen following application of EGF–Alexa 647 with tissue slice selected for IHC outlined
in white. (B) Histopathology map of specimen. (C) IHC staining of selected slice as graded by a pathologist is indicated on a scale of 0 to
3 along with the original IHC image. The fluorescence image from the corresponding portion of tissue is also shown, and fluorescence
intensity is graphed across the slice on a scale normalized to the maximum value. The original H&E slide and corresponding histologic
diagnosis are also shown for reference.
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was from 0 to 3. Score 0 indicated no staining or nonspecific staining,
score 1 was used for weak staining of more than 10% of cells, score 2
indicated moderate staining of more than 10% of cells, and score 3 in-
dicated strong and complete staining of more than 10% of cells [8].
The level of immunostaining was compared to fluorescence intensity
from the corresponding portion of tissue to further validate the corre-
lation between IHC for EGFR and EGF–Alexa 647 fluorescence.
IHC for GLUT expression was not compared with fluorescence im-
aging results with 2-NBDG, because while IHC can reveal GLUT ex-
pression level, it cannot assess GLUT activity level. Previous studies have
not found a significant correlation between overexpression of GLUTs
and standardized uptake values of FDG in FDG-PET imaging, a widely
accepted clinical method of analyzing metabolic activity [20,27].
Quantitative Analysis of Fluorescence Images
Postincubation fluorescence images of both 2-NBDG and EGF–
Alexa 647 were analyzed using Matlab R2010b software (The
MathWorks, Natick, MA) to identify trends in optical molecular
images that correlate with diagnosis. All images before and after incu-
bation were aligned using a Matlab image registration algorithm. The
fluorescence images were converted to grayscale, and background auto-
fluorescence was subtracted. For each clinical sample, multiple square
regions of interest 50 × 50 pixels in size were selected, using the histo-
pathology map as a guide to ensure that each region selected contained
a uniform diagnosis and that regions did not overlap. Image features
were calculated and compared with feature values from regions of nor-
mal tissue to determine whether these characteristics were altered with
the presence of neoplasia. These features included normalized mean in-
tensity, standard deviation, skewness, kurtosis, and the coefficient of
variation within each region. Normalization of mean intensity was per-
formed per patient; the mean of all histologically normal regions of
interest for a patient was used to normalize every region of interest se-
lected for that patient. In addition, a Matlab edge detection algorithm
using the Canny method was applied to the bulk fluorescence image to
detect where sharp gradients in intensity occurred because this may also
serve as a measure of heterogeneity of biomarker expression. The length
of this edge line divided by the number of pixels in the region was
calculated for all selected regions of interest.
Figure 3. Intensity of IHC staining and corresponding fluorescence intensity graphs for two additional specimens with two slices shown
from each: (A) specimen 2, slice M7; (B) specimen 2, slice M10; (C) specimen 6, slice H9; and (D) specimen 6, slice H4.
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Development of a Classification Algorithm
To discriminate normal from neoplastic regions of interest based
on these quantitative feature values, a classification algorithm was de-
veloped using linear discriminant analysis. The algorithm used all of
the 50 × 50 pixel regions for both training and testing. Features were
selected sequentially to identify which were most useful in distinguishing
neoplastic tissue from normal tissue. Only three features were chosen to
avoid overtraining of the algorithm. Sensitivity, specificity, and area
under the receiver operator characteristic curve (AUC) were calculated.
Application of Classification Algorithm to a New Data Set
to Predict Regions with the Highest Likelihood of Disease
We examined the ability of this algorithm to identify regions of
interest with the highest likelihood of disease, information that
could be useful for early detection and diagnosis, planning surgical
resection, monitoring treatment response, or screening for recur-
rence. A 50 × 50 pixel grid was used to divide the original fluores-
cence images from all the patients into new regions of interest. The
classification algorithm described previously was applied to these
regions to generate posterior probabilities (a value between 0 and
1) for all the new regions. The practical application of this strategy
would be to help a clinician objectively identify areas with the high-
est likelihood of disease. The regions with posterior probabilities
from 0.80 to 1.00 were identified and compared with histopathol-
ogy map information at that site. Regions with posterior probabil-
ities from 0.60 to 0.79 were also identified as regions likely to be
neoplastic, and this prediction was compared with the histopathol-
ogy gold standard to assess performance of the algorithm. Only
regions that contained epithelium throughout the entire 50 × 50 pixel
region were evaluated; regions overlapping the edge of the tissue were
not considered.
Results
Nine clinical specimens from different patients were imaged as de-
scribed; a histopathology map was created for each specimen. Figure 1
shows images from two representative clinical specimens: one with
mild to moderate dysplasia and one with cancer. Qualitative compar-
ison of the fluorescence images and the gold standard histopathology
maps of each specimen demonstrates that, for both imaging agents,
there is greater fluorescence intensity in areas of neoplasia, including
areas of invasive carcinoma as well as in areas of mild to moderate
dysplasia. Note that due to the manner in which the imaging agent
was applied, topical application at the edges of the specimen resulted
in some imaging agent coming in contact with the deep tissue. The
imaging agent is not as easily rinsed from the deep tissue, and so a
small edge effect can be observed; higher fluorescence intensity is
seen around the edges of the tissue.
IHC to Confirm EGFR Expression
IHC staining for EGFR was performed on multiple specimens to
confirm previously published findings validating the specificity of
EGF–Alexa 647 for EGFR. Figure 2 shows results from one repre-
sentative patient specimen. Figure 2A shows the wide-field EGF–
Alexa 647 fluorescence image for this specimen; a white rectangle
indicates the slice of tissue for which IHC was performed. Figure 2B
shows the corresponding histopathology map for this specimen.
Figure 2C shows the immunostained slide prepared from this slice
along with the IHC scale, indicating the pathologist’s grading of degree
of staining for EGFR. Below the IHC image is the corresponding por-
tion of the fluorescence image for comparison. The fluorescence inten-
sity was summed for each column in the fluorescence image and
normalized to the maximum value; results are shown on the fluores-
cence intensity graph in Figure 2C . Figure 2C also shows the H&E–
stained slide and H&E scale (corresponding to the histopathology map)
for reference. Regions of high fluorescence intensity correspond well
to regions of elevated IHC staining across this tissue slice, verifying
the specificity of EGF–Alexa 647. The edge effect mentioned earlier
is the cause of the slightly higher fluorescence at the edges of the tissue
that do not correlate with IHC results.
The same type of analysis was performed for four patients to ensure
consistency of results, although in this case, the edges were cropped.
Figure 3 compares the intensity of IHC staining and the graph of
normalized fluorescence intensity for two additional specimens, with
two different slices shown from each. IHC grading and fluorescence
intensity correlate well for all the slides investigated.
Quantitative Analysis of Fluorescence Images
Figure 4 shows a representative sample with the outlines of the
selected 50 × 50 pixel regions of interest. This specimen contains
four normal regions, three regions of mild dysplasia, nine regions
of moderate dysplasia, and three regions of severe dysplasia. The
Figure 4. Representative example of how 50 × 50-pixel regions of
interest were selected. This sample contains four normal regions,
three regions of mild dysplasia, nine regions of moderate dysplasia,
and three regions of severe dysplasia. Quantitative features were
calculated from each region of interest. Scale bar, 1 cm.
Table 1. Number of Analyzed Regions by Patient and Diagnosis.
Specimen No. Normal Mild Dysplasia Moderate Dysplasia Severe Dysplasia Cancer Total
1 4 3 9 3 0 19
2 18 1 1 0 12 32
3 14 3 0 15 4 36
4 12 33 8 0 0 53
5 9 6 3 2 17 37
6 9 3 3 0 23 38
7 3 2 1 0 2 8
8 6 1 1 0 23 31
9 12 5 0 0 15 32
Total 87 57 26 20 96 286
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regions are oriented parallel to the pathology slices to maximize the
number of regions that could be selected per sample. Table 1 details
the number of regions that were selected per sample by diagnostic
category. Overall, 286 total regions were selected from the nine speci-
mens and were categorized as follows: 87 normal regions, 57 regions
with mild dysplasia, 26 regions with moderate dysplasia, 20 regions
containing severe dysplasia, and 95 regions with cancer.
Development of a Classification Algorithm
For each region, image features including average intensity, stan-
dard deviation, skewness, kurtosis, maximum value, and coefficient
of variation were calculated from postincubation fluorescence images.
In addition, the length of the edge line detected using the Matlab edge
function was calculated for each region using fluorescence images.
These image features were used to train and test a classification algo-
rithm on the full set of 286 regions; a histologic diagnosis of normal
epithelium was considered normal, and mild, moderate, and severe dys-
plasia and cancer were considered neoplastic. Table 2 indicates the clas-
sification performance of the top 6 highest-performing single features,
ranked by AUC. Of the six top-performing features, four are calculated
from the EGF–Alexa 647 image and two are calculated from the 2-
NBDG image. Normalized mean intensity of the EGF–Alexa 647 sig-
nal was the highest performing single feature with an AUC of 0.80.
Figure 5 shows scatterplots of two selected features of interest,
with the y axis indicating feature value and the x axis sorted by path-
ologic diagnosis. Each of the 286 points in the graph indicates a single
region of interest. Figure 5A shows normalized mean intensity of the
2-NBDG signal and Figure 5B shows normalized mean intensity of
the EGF–Alexa 647 signal. Regions are grouped by pathologic diag-
nosis with green indicating normal epithelium, blue indicating mild
dysplasia, pink indicating moderate dysplasia, red indicating severe
dysplasia, and black indicating cancer. Horizontal black lines indicate
the mean feature value and vertical black lines indicate ±1 standard
deviation for each pathologic category. Figure 5 indicates that the
2-NBDG signal intensity, and therefore metabolic activity, is elevated
earlier in the progression of neoplasia, whereas EGFR expression is
elevated later in this progression.
Ultimately, three unbiased features were selected for use in the clas-
sification algorithm: (1) normalized mean intensity of the EGF–Alexa
647 signal, (2) coefficient of variation from the 2-NBDG signal, and
(3) length of the detected edge based on 2-NBDG. The features were
selected sequentially in that order for improving performance of the
algorithm; the normalized mean intensity of the EGF–Alexa 647 sig-
nal was the single best feature, and each of the subsequent features
improved algorithm performance. Addition of a fourth feature did
not significantly improve performance. Table 2 also indicates the
AUC of the three-feature algorithm developed from this combination
of quantitative features.
Figure 6A shows the resulting scatterplot of posterior probabilities
grouped by histopathologic diagnosis. The horizontal line at 0.41 in-
dicates the cutoff point that gives the best sensitivity and specificity
of the algorithm. Any posterior probability above this value would be
considered neoplastic by the classification algorithm, and any poste-
rior probability below this value would be considered normal. This
cutoff gives a sensitivity of 73% and a specificity of 77%. Figure 6B
shows the receiver operator characteristic curve of the algorithm. The
AUC is 0.83, and the cutoff point yielding the highest sensitivity and
specificity is marked with a blue circle.
Figure 7A displays the 50 × 50-pixel grid that was used to divide
the image from a representative sample into new regions. Whereas
Figure 5. Scatterplots showing the distribution of feature values within the set of 286 regions; each point represents a single region.
Regions are grouped by pathologic diagnosis with green indicating normal epithelium, blue indicating mild dysplasia, pink indicating
moderate dysplasia, red indicating severe dysplasia, and black indicating cancer. Horizontal black lines indicate the mean feature value
and vertical black lines indicate ±1 standard deviation for each pathologic category. The scatterplots show the following features: (A)
mean intensity of the 2-NBDG signal and (B) mean intensity of the EGF–Alexa 647 signal.
Table 2. Performance of Single Features and Combination of Features in a Classification Algorithm.
Feature AUC of Feature
EGF normalized mean intensity 0.80
EGF entropy 0.76
EGF standard deviation 0.73
2-NBDG normalized mean intensity 0.70
EGF maximum value 0.70
2-NBDG maximum value 0.68
Three-feature algorithm 0.83
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the originally evaluated regions as shown in Figure 4 were selected to
contain only one diagnostic category and were oriented parallel to the
pathology slices, the new evaluation grid is oriented parallel to the
edges of the image and each region may contain multiple diagnostic
categories. Figure 7B indicates the regions that were identified as hav-
ing the highest posterior probability. Black stars indicate a posterior
probability between 0.80 and 1.00 and gray stars indicate a posterior
probability between 0.60 and 0.79. In this example, two adjacent
regions have the highest level of posterior probability. According to
the histopathology map, one of these regions contains mostly severe
dysplasia, and the other contains mostly moderate dysplasia. Two
regions with the second highest level of posterior probability were
also identified, and these are also adjacent to one of the highest-level
regions. Of these two regions, marked with a gray star, one contains
mostly severe dysplasia and the other contains moderate dysplasia
throughout. No part of any of these identified regions in this spec-
imen contains normal epithelium.
This method was applied to all nine specimens; results are shown in
Table 3. Of the nine specimens, seven specimens contained at least
one region that had a posterior probability between 0.80 and 1.00, for
a total of 85 regions. Of these identified regions, 99% (84/85)
contained more than 50% neoplasia. The remaining two specimens
that did not have any regions identified within the highest-level cat-
egory (nos. 3 and 7) had multiple regions with posterior probabilities
between 0.60 and 0.79. Among the nine specimens, a total of 85 dif-
ferent regions were identified as having a posterior probability from
0.60 to 0.79. Of these regions, 95% (81/85) contained more than
50% neoplasia.
Figure 8 shows for all the clinical samples the regions determined
to have the highest posterior probability overlaid onto the corre-
sponding histopathology maps. The black stars indicate the regions with
posterior probability from 0.80 to 1.00, and the gray stars indicate the
regions with posterior probability from 0.60 to 0.79. A few of the
regions identified do not have corresponding gold standard histo-
pathology information for the entire area and so were not included
in the analysis shown in Table 3, but are shown in Figure 8.
This strategy has excellent agreement with histopathology, and
although it does not identify all abnormal tissue, it identifies areas
with the highest likelihood of disease in all samples.
Discussion
The optical imaging approach described in this study uses molecularly
targeted contrast agents to simultaneously assess two clinically rele-
vant biomarkers in oral cancer: EGFR expression and metabolic ac-
tivity. The benefit of this approach is that expression levels of multiple
biomarkers can be assessed quantitatively over a large field of view and
with high spatial resolution; this type of information cannot be ob-
tained through the current practice of IHC. In this study, we used
ex vivo imaging to evaluate whether topical application of multiple
imaging agents could be potentially useful to predict the presence
of neoplastic disease in the oral cavity. A potential advantage of study-
ing optical imaging approaches in freshly resected human tissue as an
alternative to in vivo assessments in animal models is that the pattern
of biomarker expression and the potential barriers to topical admin-
istration of imaging agents will likely be more physiologically rele-
vant to the intended final goal of in vivo imaging of patients with
oral cancer [28].
The optical molecular imaging approach demonstrated here ex vivo
can be translated to in vivo oral cavity imaging. The imaging system
used in this study has been used to measure oral autofluorescence
in vivo in many patients [26,29,30]. The targeted imaging agents can
be formulated into a mouthwash solution or topical gel that could be
topically applied to the oral mucosal surface, potentially decreasing the
dose required in comparison with intravenous injection and reducing
consequent systemic toxicity concerns. Imaging could be performed
shortly after application. Steps remaining before this technique can
be translated to in vivo use in patients include safety testing to support
an Investigational New Drug application for topical use of the imaging
agents. This would allow clinical testing to assess the utility of the tech-
nique in patients with oral dysplasia or cancer. This approach could also
be extended to include other biomarkers, if spectrally distinct imaging
agents that specifically target the biomarker can be developed.
Analysis of fluorescence images in Figure 6 revealed features that
differ in images of normal and neoplastic tissue.Whereas using the clas-
sification algorithm to simply classify a site as either normal or neo-
plastic resulted in a sensitivity of 73% and a specificity of 77%, the
Figure 6. (A) Scatterplot of posterior probability by diagnosis using
the algorithm. The horizontal line indicates the optimum cutoff at
0.41. The color key is the same as in Figure 5. (B) Receiver oper-
ator characteristic curve using a three-feature classification algo-
rithm. The operating point at the optimum cutoff is shown with
a blue circle and results in a sensitivity of 73%, a specificity of
77%, and an AUC of 0.83.
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plot of posterior probability versus diagnosis suggests a more useful way
in which to apply the image features. When these image features were
used to identify regions with the highest likelihood of disease, the se-
lected areas contained histologically diagnosed neoplasia 99% of the
time. The advantages of the quantitative features used for classification
are that they provide objective metrics that reflect the amount of the
molecular target present and the heterogeneity of the target expression.
These features can be calculated rapidly and easily. The objective assess-
ment to accurately predict the presence of neoplasia has many clinical
applications, including initial detection and diagnosis, selection of an
appropriate biopsy site, monitoring treatment response, and monitor-
ing patients for recurrence. This application is consistent with research
recommended in 2010 in the Journal of the American Dental Associ-
ation, which called for research projects to “identify factors that would
increase clinicians’ confidence and competence in identification and
management of potentially malignant lesions or early-stage malignan-
cies, including the provision of surgical biopsies” [31].
Another potential use of a targeted optical imaging strategy could
be in understanding the role of heterogeneity of biomarker expression
in selection of therapy and predicting treatment response. Quantita-
tive IHC studies reveal that the factor of overexpression of EGFR
ranges from approximately 1.7- to 3-fold increase in dysplasia and
cancer [13,14,32]. A similar level of overexpression has also been ob-
served in targeted molecular imaging studies, and the results of this
study are comparable [22,33]. EGFR expression is already a target
in the FDA-approved monoclonal antibody therapy cetuximab,
which is often used to treat recurrence of oral cancer. Other EGFR
inhibitors (gefitinib, erlotinib, panatumumab, and lapatinib) have
been approved for cancer treatment in other organ sites and are cur-
rently in clinical trials for head and neck cancer indications [34].
Whereas in vitro data suggest a link between EGFR expression level
and cytotoxicity of EGFR-targeted therapy, no definitive clinical cor-
relation has yet been found [35–37]. As seen in the fluorescence
images and IHC data shown here, EGFR expression is heterogeneous
throughout a lesion. The ability to assess biomarker expression in vivo
over a large sample using optical molecular imaging may elucidate the
causes of this discrepancy and aid in the selection of patients who
could benefit from EGFR-targeted therapy. For patients who re-
spond, the benefits of EGFR-targeted therapy include the prevention
of nodal metastases by blocking EGFR and potentially improved
survival when combined with standard chemotherapy [38,39]. As
new EGFR-targeted therapies (such as nimotuzumab, zalutulumab,
bevacizumab, and vandetanib) are developed and tested clinically for
head and neck cancer indications, predicting which patients may ben-
efit from a particular therapy will also aid in FDA approval [40,41].
EGFR expression also has applications in other clinical settings.
EGFR may help distinguish between leukoplakia with or without
dysplasia because oral leukoplakia with underlying dysplasia has in-
creased expression of EGFR, which may be useful as an early marker
of malignancy [15]. Moreover, nonmalignant leukoplakias were
shown not to have elevated EGFR expression [42]. Another clinical
application of EGFR expression is in the identification of patients
who would benefit from hyperfractionated accelerated radiotherapy
[43,44]. In pretreatment biopsies assessed for EGFR, patients with
high EGFR expression had improved survival with hyperfractionated
accelerated radiotherapy compared with a standard radiotherapy
schedule. Identifying EGFR expression across the entire surface of
Figure 7. (A) Superimposed grid to divide each specimen into a new set of regions of interest. Using the previously developed classi-
fication algorithm, posterior probabilities were calculated for each of these new regions of interest. (B) On the basis of two levels of
posterior probability, regions identified as most likely to contain neoplasia were marked with black (posterior probability = 0.80-1.00) or
gray (posterior probability = 0.60-0.79) stars. Scale bars, 1 cm.
Table 3. Use of Posterior Probability to Identify Regions with the Highest Likelihood of Disease.
Specimen No. Regions with Posterior Probability
of 0.80-1.00
Regions with Posterior Probability
of 0.60-0.79
1 100% (2/2) 100% (2/2)
2 93% (13/14) 80% (4/5)
3 N/A 50% (1/2)
4 100% (1/1) 100% (15/15)
5 100% (25/25) 80% (8/10)
6 100% (31/31) 100% (8/8)
7 N/A 100% (3/3)
8 100% (11/11) 100% (24/24)
9 100% (1/1) 100% (16/16)
Total 99% (84/85) 95% (81/85)
Values are presented as percentage of regions containing more than 50% neoplasia.
N/A indicates not applicable.
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the lesion may improve identification of patients who could benefit
from this type of treatment. Finally, quantification of EGFR expression
is difficult with current IHC methods, which may be one reason for
conflicting findings in studies examining the prognostic value of EGFR
in head and neck cancer [8]. Quantitative evaluation of optical molec-
ular imaging of EGFR may help standardize measurement of EGFR
expression level.
Metabolic activity as indicated by FDG-PET is currently used ex-
tensively in head and neck cancer for tumor staging, monitoring treat-
ment response, and detecting residual or recurrent disease [45,46].
FDG-PET has a high sensitivity and moderate specificity for detect-
ing recurrent disease at the primary tumor site, but because of its
inherently low spatial resolution, it is unable to detect lesions smaller
than approximately 1 cm in size [46]. FDG-PET is significantly better
than clinical assessment and conventional imaging to monitor treat-
ment response and has also been used as a marker of erlotinib response
[47,48]. Monitoring metabolic activity with FDG-PET can also iden-
tify residual disease and detect recurrence [46,47,49–51]. Although
monitoring metabolic activity optically with 2-NBDG cannot accom-
plish any of the deep tissue applications of FDG-PET such as imaging
of nodal metastases, it can be used to assess metabolic activity in the
epithelium as shown in this study, a strategy that may be useful to
detect residual or recurrent disease at the primary tumor site. The ad-
vantage of using 2-NBDG over FDG-PET is that optical imaging
provides superior spatial and temporal resolution, does not expose
the patient to ionizing radiation, and is far less expensive than PET
imaging equipment and maintenance of cyclotron facilities.
Optical molecular imaging as applied in this study has some lim-
itations, however. Although topical application of imaging agents
may reduce dose and toxicity concerns, the agents are delivered only
in the epithelium, preventing detection of submucosal disease. An-
other concern may arise from the idea of applying the EGF, a mitogen,
to a potentially neoplastic area. However, studies have demonstrated
that pretreatment of oral cancer lesions with EGF actually improves
the cytotoxicity of cisplatin, the most commonly used chemother-
apy for head and neck cancer [52,53]. Inflammation in the oral
cavity is a common confounder for detection of neoplasia, and in-
flammatory cells may also take up 2-NBDG, resulting in potential
false-positives from high metabolic activity of lymphocytes present
in the oral tissue due to benign conditions. However, targeting
GLUTs is still very clinically relevant as evidenced by the wide-
spread use of FDG-PET imaging. Having an orthogonal target such
as EGFR is useful to prevent the occasional false-positive from 2-
NBDG signal due to inflammation because EGFR is not elevated
as a result of inflammation. Finally, not all patients will have over-
expression of EGFR, so that low fluorescence signal after application
Figure 8. All clinical specimens; regions identified by the algorithm as most likely to contain neoplasia are marked by stars. Black stars
indicate the highest level of posterior probability (0.80-1.00) and gray stars indicate the next highest level of posterior probability (0.60-
0.79). Regions predicted to contain neoplasia have excellent agreement with the criterion standard of histopathology. Scale bars, 1 cm.
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of EGF–Alexa 647 may not rule out the possibility of the presence
of neoplasia.
Being able to obtain information from both agents in combination
may help avoid the pitfalls of each agent alone. As seen from the images
in Figure 1 and the quantitative results in Figure 5, although the general
spatial pattern of staining with both agents appears similar with ele-
vation across regions of neoplasia, there are important differences. 2-
NBDG signal is most elevated in regions with histologic diagnosis of
dysplasia, and EGFR signal is most elevated in regions with histologic
diagnosis of cancer. The changes in 2-NBDG signal over progression of
disease is related first to rapid growth and metabolism of cells during
dysplasia, followed by necrosis and ulceration that occurs once a large
tumor develops. EGFR expression increases over disease progression
and is at its highest once cancer develops. 2-NBDG and EGFR there-
fore provide complementary information.
Biomarkers have been studied for their potential use in detecting
neoplasia, staging, selecting and monitoring therapy, detection of
recurrence, and prognostic value, but the full picture of biomarker
expression across an entire lesion is necessary to make accurate con-
clusions about the roles these biomarkers play in the disease process.
Optical molecular imaging as demonstrated in this study of EGFR
expression and metabolic activity in oral mucosa can reveal biomarker
heterogeneity across a lesion and may serve as a research tool to under-
stand cancer biology, develop new targeted therapies, or aid in the clin-
ical management of cancer patients. With the proper imaging agents,
this approach could be extended to monitor additional biomarkers in
other types of epithelial neoplasia as well and may eventually result in
improved patient survival by allowing clinical care to be tailored to each
patient’s biomarker expression profile.
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